{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:51:27Z","timestamp":1787698287655,"version":"build-2784847793"},"reference-count":128,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) remains a significant challenge in the field of neurodegenerative disorders, even nearly a century after its discovery, due to the elusive nature of its causes. The development of drugs that target multiple aspects of the disease has emerged as a promising strategy to address the complexities of AD and related conditions. The immune system\u2019s role, particularly in AD, has gained considerable interest, with nanobodies representing a new frontier in biomedical research. Advances in targeting antibodies against amyloid-\u03b2 (A\u03b2) and using messenger RNA for genetic translation have revolutionized the production of antibodies and drug development, opening new possibilities for treatment. Despite these advancements, conventional therapies for AD, such as Cognex, Exelon, Razadyne, and Aricept, often have limited long-term effectiveness, underscoring the need for innovative solutions. This necessity has led to the incorporation advanced technologies like artificial intelligence and machine learning into the drug discovery process for neurodegenerative diseases. These technologies help identify therapeutic targets and optimize lead compounds, offering a more effective approach to addressing the challenges of AD and similar conditions.<\/jats:p>","DOI":"10.3390\/ph17060741","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T08:45:37Z","timestamp":1717663537000},"page":"741","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Innovative Therapeutic Strategies in Alzheimer\u2019s Disease: A Synergistic Approach to Neurodegenerative Disorders"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-0336","authenticated-orcid":false,"given":"Sarfaraz K.","family":"Niazi","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Illinois, Chicago, IL 60012, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Magoola","sequence":"additional","affiliation":[{"name":"DEI Biopharma, Kampala P.O. Box 35854, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-9559","authenticated-orcid":false,"given":"Zamara","family":"Mariam","sequence":"additional","affiliation":[{"name":"Centre for Health and Life Sciences, Coventry University, Coventry CV1 5FB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ciurea, A.V., Mohan, A.G., Covache-Busuioc, R.A., Costin, H.P., Glavan, L.A., Corlatescu, A.D., and Saceleanu, V.M. (2023). Unraveling molecular and genetic insights into neurodegenerative diseases: Advances in understanding Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s diseases and amyotrophic lateral sclerosis. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202305.1229.v1"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lamptey, R.N.L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., and Singh, J. (2022). A review of the common neurodegenerative disorders: Current therapeutic approaches and the potential role of nanotherapeutics. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031851"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.biopsych.2021.05.025","article-title":"Traumatic brain injury and risk of neurodegenerative disorder","volume":"91","author":"Brett","year":"2022","journal-title":"Biol. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1007315","DOI":"10.3389\/fphar.2022.1007315","article-title":"Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues","volume":"13","author":"Kakoti","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fnins.2018.00047","article-title":"Open science meets stem cells: A new drug discovery approach for neurodegenerative disorders","volume":"12","author":"Han","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e12295","DOI":"10.1002\/trc2.12295","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1002\/alz.13428","article-title":"Artificial intelligence for dementia drug discovery and trials optimization","volume":"19","author":"Doherty","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_8","first-page":"729","article-title":"The critical role of biomarkers for drug development targeting the biology of aging","volume":"10","author":"Owen","year":"2023","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3233\/JAD-191266","article-title":"A single-chain variable fragment antibody inhibits aggregation of phosphorylated tau and ameliorates tau toxicity in vitro and in vivo","volume":"79","author":"Li","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1755-5949.2010.00177.x","article-title":"The role of tau in Alzheimer\u2019s disease and related disorders","volume":"17","author":"Medeiros","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kumari, S., Mehta, S.L., and Li, P.A. (2012). Glutamate induces mitochondrial dynamic imbalance and autophagy activation: Preventive effects of selenium. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039382"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"18586","DOI":"10.1038\/s41598-023-45878-7","article-title":"Moschus ameliorates glutamate-induced cellular damage by regulating autophagy and apoptosis pathway","volume":"13","author":"Xie","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.me.40.020189.000401","article-title":"The pathobiology of Alzheimer\u2019s disease","volume":"40","author":"Glenner","year":"1989","journal-title":"Annu. Rev. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10836","DOI":"10.1073\/pnas.90.22.10836","article-title":"beta-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease","volume":"90","author":"Roher","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/pro.2524","article-title":"A brief overview of amyloids and Alzheimer\u2019s disease","volume":"23","author":"Ow","year":"2014","journal-title":"Protein Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/agm2.12243","article-title":"Neurodegenerative disorders: Assessing the impact of natural vs drug-induced treatment options","volume":"6","author":"Mathur","year":"2023","journal-title":"Aging Med. (Milton)."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-022-00524-0","article-title":"Solving neurodegeneration: Common mechanisms and strategies for new treatments","volume":"17","author":"Wareham","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Verma, A., Waiker, D.K., Bhardwaj, B., Saraf, P., and Shrivastava, S.K. (2022). The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer\u2019s disease. Bioorganic Chem., 119.","DOI":"10.1016\/j.bioorg.2021.105562"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cheong, S.L., Tiew, J.K., Fong, Y.H., Leong, H.W., Chan, Y.M., Chan, Z.L., and Kong, E.W.J. (2022). Current pharmacotherapy and multi-target approaches for Alzheimer\u2019s disease. Pharmaceuticals, 15.","DOI":"10.3390\/ph15121560"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","article-title":"Shifting from the single to the multitarget paradigm in drug discovery","volume":"18","author":"Giulianotti","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fphar.2015.00205","article-title":"Multi-target pharmacology: Possibilities and limitations of the \"skeleton key approach\" from a medicinal chemist perspective","volume":"6","author":"Talevi","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential impact of the multi-target drug approach in the treatment of some complex diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Des. Devel Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"730257","DOI":"10.3389\/fphar.2021.730257","article-title":"Single-target versus multi-target drugs versus combinations of drugs with multiple targets: Preclinical and clinical evidence for the treatment or prevention of epilepsy","volume":"12","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1474-4422(16)30001-1","article-title":"Treating neurodegenerative disease before illness: A challenge for the 21st century","volume":"15","author":"Kieburtz","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_25","first-page":"563481","article-title":"Neurodegenerative diseases: Multifactorial conformational diseases and their therapeutic interventions","volume":"2013","author":"Sheikh","year":"2013","journal-title":"J. Neurodegener. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1080\/21655979.2021.2022262","article-title":"Safinamide protects against amyloid \u03b2 (A\u03b2)-induced oxidative stress and cellular senescence in M17 neuronal cells","volume":"13","author":"Gu","year":"2022","journal-title":"Bioengineered"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e12435","DOI":"10.1002\/trc2.12435","article-title":"One step forward to personalized medicine?","volume":"9","author":"Dodge","year":"2023","journal-title":"Alzheimer\u2019s Dement"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mito.2023.05.007","article-title":"Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease, and Parkinson\u2019s disease, Huntington\u2019s disease and amyotrophic lateral sclerosis: An updated review","volume":"71","author":"Alqahtani","year":"2023","journal-title":"Mitochondrion"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer\u2019s disease: The path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.2174\/1381612825666191011102444","article-title":"NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer\u2019s therapy","volume":"25","author":"Kabir","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"134836","DOI":"10.1016\/j.scitotenv.2019.134836","article-title":"Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer\u2019s disease","volume":"700","author":"Uddin","year":"2020","journal-title":"Sci. Total Environ."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2147\/DDDT.S86463","article-title":"A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer\u2019s disease","volume":"10","author":"Deardorff","year":"2016","journal-title":"Drug Des. Devel Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kabir, M.T., Uddin, M.S., Mamun, A.A., Jeandet, P., Aleya, L., Mansouri, R.A., Ashraf, G.M., Mathew, B., Bin-Jumah, M.N., and Abdel-Daim, M.M. (2020). Combination drug therapy for the management of Alzheimer\u2019s disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093272"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11095-010-0065-2","article-title":"In-silico approaches to multi-target drug discovery: Computer aided multi-target drug design, multi-target virtual screening","volume":"27","author":"Ma","year":"2010","journal-title":"Pharm. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13ra1","DOI":"10.1126\/scitranslmed.3000337","article-title":"Modeling an anti-amyloid combination therapy for Alzheimer\u2019s","volume":"2","author":"Chow","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/156720509787602861","article-title":"Cholinesterase inhibitors and beyond","volume":"6","author":"Pepeu","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1517\/13543776.2012.701620","article-title":"Acetylcholinesterase inhibitors: A patent review (2008-present)","volume":"22","author":"Pohanka","year":"2012","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/ph7020113","article-title":"From single target to multitarget\/network therapeutics in Alzheimer\u2019s therapy","volume":"7","author":"Zheng","year":"2014","journal-title":"Pharmaceuticals"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Plazas, E., Hagenow, S., Avila Murillo, M., Stark, H., and Cuca, L.E. (2020). Isoquinoline alkaloids from the roots of Zanthoxylum rigidum as multi-target inhibitors of cholinesterase, monoamine oxidase A and A\u03b2(1-42) aggregation. Bioorg Chem., 98.","DOI":"10.1016\/j.bioorg.2020.103722"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejmech.2019.02.008","article-title":"Synthesis and evaluation of tetrahydroisoquinoline-benzimidazole hybrids as multifunctional agents for the treatment of Alzheimer\u2019s disease","volume":"167","author":"Fang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejmech.2019.01.030","article-title":"Indazolylketones as new multitarget cannabinoid drugs","volume":"166","author":"Roca","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ivanova, L., Karelson, M., and Dobchev, D.A. (2020). Multitarget approach to drug candidates against Alzheimer\u2019s disease related to AChE, SERT, BACE1 and GSK3\u03b2 protein targets. Molecules, 25.","DOI":"10.3390\/molecules25081846"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"824888","DOI":"10.3389\/fnins.2022.824888","article-title":"Microglia and astrocyte function and communication: What do we know in humans?","volume":"16","author":"Garland","year":"2022","journal-title":"Front. Neurosci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"627325","DOI":"10.1155\/2013\/627325","article-title":"Microglia: An active player in the regulation of synaptic activity","volume":"2013","author":"Ji","year":"2013","journal-title":"Neural Plast."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: Mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Toader, C., Dobrin, N., Brehar, F.M., Popa, C., Covache-Busuioc, R.A., Glavan, L.A., Costin, H.P., Bratu, B.G., Corlatescu, A.D., and Popa, A.A. (2023). From recognition to remedy: The significance of biomarkers in neurodegenerative disease pathology. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216119"},{"key":"ref_48","first-page":"1003","article-title":"Neuroinflammation induces neurodegeneration","volume":"1","author":"Kempuraj","year":"2016","journal-title":"J. Neurol. Neurosurg. Spine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainres.2014.09.008","article-title":"The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?","volume":"1617","author":"Doty","year":"2015","journal-title":"Brain Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/s13311-015-0385-3","article-title":"Neuroinflammation: Ways in which the immune system affects the brain","volume":"12","author":"Ransohoff","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1127704","DOI":"10.3389\/fimmu.2023.1127704","article-title":"Immunomodulation-a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system","volume":"14","author":"Strzelec","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1201982","DOI":"10.3389\/fnagi.2023.1201982","article-title":"Microglia in Alzheimer\u2019s disease: Pathogenesis, mechanisms, and therapeutic potentials","volume":"15","author":"Miao","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.molmed.2017.03.008","article-title":"TREM2, microglia, and neurodegenerative diseases","volume":"23","author":"Yeh","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer\u2019s disease","volume":"13","author":"Gratuze","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fncel.2018.00458","article-title":"The interleukin-10 family of cytokines and their role in the CNS","volume":"12","author":"Burmeister","year":"2018","journal-title":"Front. Cell Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12974-016-0763-8","article-title":"Balancing the immune response in the brain: IL-10 and its regulation","volume":"13","author":"Carriche","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"ref_58","unstructured":"Food and Drug Administration (2024, February 24). FDA Grants Accelerated Approval for Alzheimer\u2019s Disease Treatment, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3233\/JAD-230526","article-title":"Reduced prevalence of dementia in patients prescribed tacrolimus, sirolimus, or cyclosporine","volume":"95","author":"Silva","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hill, J., and Zawia, N.H. (2021). Fenamates as potential therapeutics for neurodegenerative disorders. Cells, 10.","DOI":"10.3390\/cells10030702"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Bindu, S., Mazumder, S., and Bandyopadhyay, U. (2020). Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem. Pharmacol., 180.","DOI":"10.1016\/j.bcp.2020.114147"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for Alzheimer\u2019s disease: Targeting \u03b2-amyloid and beyond","volume":"11","author":"Song","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"ref_63","first-page":"89","article-title":"Bapineuzumab, an investigational agent for Alzheimer\u2019s disease","volume":"38","author":"Khorassani","year":"2013","journal-title":"Pharm. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Abushouk, A.I., Elmaraezy, A., Aglan, A., Salama, R., Fouda, S., Fouda, R., and AlSafadi, A.M. (2017). Bapineuzumab for mild to moderate Alzheimer\u2019s disease: A meta-analysis of randomized controlled trials. BMC Neurol., 17.","DOI":"10.1186\/s12883-017-0850-1"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Gugliandolo, A., Bramanti, P., and Mazzon, E. (2017). Role of vitamin E in the treatment of Alzheimer\u2019s disease: Evidence from animal models. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122504"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2147\/CIA.S186760","article-title":"Vitamin E and Alzheimer\u2019s disease: What do we know so far?","volume":"14","author":"Browne","year":"2019","journal-title":"Clin. Interv. Aging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"630s","DOI":"10.1093\/ajcn\/71.2.630s","article-title":"Vitamin E and Alzheimer disease: The basis for additional clinical trials","volume":"71","author":"Grundman","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Numakawa, T., and Kajihara, R. (2023). Neurotrophins and other growth factors in the pathogenesis of Alzheimer\u2019s disease. Life, 13.","DOI":"10.3390\/life13030647"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"331","DOI":"10.14336\/AD.2015.0825","article-title":"The involvement of BDNF, NGF and GDNF in aging and Alzheimer\u2019s disease","volume":"6","author":"Budni","year":"2015","journal-title":"Aging Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","article-title":"Brain-derived neurotrophic factor and its clinical implications","volume":"11","author":"Bathina","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40035-022-00279-0","article-title":"Brain-derived neurotrophic factor in Alzheimer\u2019s disease and its pharmaceutical potential","volume":"11","author":"Gao","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e2300258120","DOI":"10.1073\/pnas.2300258120","article-title":"Structure-based design of nanobodies that inhibit seeding of Alzheimer\u2019s patient-extracted tau fibrils","volume":"120","author":"Abskharon","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"978513","DOI":"10.3389\/fimmu.2022.978513","article-title":"Applications of nanobodies in brain diseases","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Atarhouch","year":"1993","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/17425247.2023.2292697","article-title":"Targeted transport of biotherapeutics at the blood-brain barrier","volume":"20","author":"Moos","year":"2023","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ebiom.2016.04.028","article-title":"Nanobodies as versatile tools to understand, diagnose, visualize and treat cancer","volume":"8","author":"Gettemans","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.2147\/IJN.S444115","article-title":"Current anti-amyloid-\u03b2 therapy for Alzheimer\u2019s disease treatment: From clinical research to nanomedicine","volume":"18","author":"Zhao","year":"2003","journal-title":"Int. J. Nanomed."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Paudel, Y.N., Angelopoulou, E., Piperi, C., Othman, I., Aamir, K., and Shaikh, M.F. (2020). Impact of HMGB1, RAGE, and TLR4 in Alzheimer\u2019s disease (AD): From risk factors to therapeutic targeting. Cells, 9.","DOI":"10.3390\/cells9020383"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Saeed, A.F., Wang, R., Ling, S., and Wang, S. (2017). Antibody engineering for pursuing a healthier future. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.00495"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.2174\/1381612822666160921143011","article-title":"Engineered autonomous human variable domains","volume":"22","author":"Nilvebrant","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: Pursuit of the \u2018high-hanging fruit\u2019","volume":"17","author":"Carter","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Amano, A., Sanjo, N., Araki, W., Anraku, Y., Nakakido, M., Matsubara, E., Tomiyama, T., Nagata, T., Tsumoto, K., and Kataoka, K. (2023). Peripheral administration of nanomicelle-encapsulated anti-A\u03b2 oligomer fragment antibody reduces various toxic A\u03b2 species in the brain. J. Nanobiotechnol., 21.","DOI":"10.1186\/s12951-023-01772-y"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2249.2002.01905.x","article-title":"Generation of a recombinant Fab antibody reactive with the Alzheimer\u2019s disease-related Abeta peptide","volume":"129","author":"Tammer","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/08923973.2015.1102934","article-title":"Single-domain antibodies for biomedical applications","volume":"38","author":"Krah","year":"2016","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"654611","DOI":"10.3389\/fphar.2021.654611","article-title":"Application of antibody fragments against A\u03b2 with emphasis on combined application with nanoparticles in Alzheimer\u2019s disease","volume":"12","author":"Sun","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4103\/1673-5374.353484","article-title":"Targeting neuroinflammation in Alzheimer\u2019s disease: From mechanisms to clinical applications","volume":"18","author":"Si","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12033-020-00241-3","article-title":"Expression of single chain variable fragment (scFv) molecules in plants: A comprehensive update","volume":"62","author":"Satheeshkumar","year":"2020","journal-title":"Mol. Biotechnol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-0716-1450-1_8","article-title":"Production of therapeutic single-chain variable fragments (ScFv) in Pichia pastoris","volume":"2313","author":"Villegas","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Fan, X., Xu, L., Zhang, J., Wang, Y., Wu, Z., Sun, W., Yao, X., Wang, X., Guan, S., and Shan, Y. (2023). Mechanism exploration of amyloid-\u03b2-42 disaggregation by single-chain variable fragments of Alzheimer\u2019s disease therapeutic antibodies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098371"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"11268","DOI":"10.1038\/s41598-017-11594-2","article-title":"Anti-A\u03b2 single-chain variable fragment antibodies restore memory acquisition in a Drosophila model of Alzheimer\u2019s disease","volume":"7","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401--a clinical study in Alzheimer\u2019s disease with a protofibril selective Abeta antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"eaau3333","DOI":"10.1126\/sciadv.aau3333","article-title":"Porphyromonas gingivalis in Alzheimer\u2019s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors","volume":"5","author":"Dominy","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1021\/jacs.1c10173","article-title":"Kinetic modulation of amyloid-beta (1-42) aggregation and toxicity by structure-based rational design","volume":"144","author":"Im","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1021\/acschemneuro.2c00504","article-title":"Role of hydrophobicity at the N-terminal region of Abeta42 in secondary nucleation","volume":"13","author":"Thacker","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.19.1.275","article-title":"IgG Fc receptors","volume":"19","author":"Ravetch","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"ref_98","unstructured":"Janeway, C., and Janeway, C. (2001). Immunobiology: The Immune System in Health and Disease, Garland Pub. [5th ed.]."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","article-title":"Basic local alignment search tool","volume":"215","author":"Altschul","year":"1990","journal-title":"J. Mol. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"D36","DOI":"10.1093\/nar\/gks1195","article-title":"GenBank","volume":"41","author":"Benson","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/pro.3781","article-title":"Shortcuts for faster image creation in PyMOL","volume":"29","author":"Mooers","year":"2020","journal-title":"Protein Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: Structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e090922208713","DOI":"10.2174\/1570163819666220909114900","article-title":"In-silico designing of a multi-epitope vaccine against SARS-CoV2 and studying the interaction of the vaccine with alpha, beta, delta and Omicron variants of concern","volume":"20","author":"Pal","year":"2023","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nprot.2016.169","article-title":"The ClusPro web server for protein-protein docking","volume":"12","author":"Kozakov","year":"2017","journal-title":"Nat. Protoc."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1073\/pnas.1908052116","article-title":"mRNA structure regulates protein expression through changes in functional half-life","volume":"116","author":"Mauger","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.18632\/aging.205018","article-title":"Integrated clustering signature of genomic heterogeneity, stemness and tumor microenvironment predicts glioma prognosis and immunotherapy response","volume":"15","author":"Wu","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"17342","DOI":"10.1073\/pnas.0506723102","article-title":"3D structure of Alzheimer\u2019s amyloid-beta(1-42) fibrils","volume":"102","author":"Ritter","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"8876","DOI":"10.1523\/JNEUROSCI.19-20-08876.1999","article-title":"Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons","volume":"19","author":"Hartley","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1126\/science.1079469","article-title":"Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis","volume":"300","author":"Kayed","year":"2003","journal-title":"Science"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e2300215120","DOI":"10.1073\/pnas.2300215120","article-title":"Multiomic prediction of therapeutic targets for human diseases associated with protein phase separation","volume":"120","author":"Lim","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Merchant, J.P., Zhu, K., Henrion, M.Y.R., Zaidi, S.S.A., Lau, B., Moein, S., Alamprese, M.L., Pearse, R.V., Bennett, D.A., and Ertekin-Taner, N. (2023). Predictive network analysis identifies JMJD6 and other potential key drivers in Alzheimer\u2019s disease. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-04791-5"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Silva-Sp\u00ednola, A., Baldeiras, I., Arrais, J.P., and Santana, I. (2022). The road to personalized medicine in Alzheimer\u2019s disease: The use of artificial intelligence. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020315"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Arru\u00e9, L., Cigna-M\u00e9ndez, A., Barbosa, T., Borrego-Mu\u00f1oz, P., Struve-Villalobos, S., Oviedo, V., Mart\u00ednez-Garc\u00eda, C., Sep\u00falveda-Lara, A., Mill\u00e1n, N., and M\u00e1rquez Montesinos, J.C.E. (2022). New drug design avenues targeting Alzheimer\u2019s disease by pharmacoinformatics-aided tools. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091914"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Kumar, S., Chowdhury, S., and Kumar, S. (2017). In silico repurposing of antipsychotic drugs for Alzheimer\u2019s disease. BMC Neurosci., 18.","DOI":"10.1186\/s12868-017-0394-8"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: Bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.biomaterials.2005.11.016","article-title":"Nerve growth factor expression by PLG-mediated lipofection","volume":"27","author":"Whittlesey","year":"2006","journal-title":"Biomaterials"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0076-6879(06)06027-7","article-title":"Nucleofection of primary neurons","volume":"406","author":"Collin","year":"2006","journal-title":"Methods Enzymol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/78523","article-title":"Enhancement of transfection by physical concentration of DNA at the cell surface","volume":"18","author":"Luo","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s11095-007-9324-2","article-title":"Drug targeting to the brain","volume":"24","author":"Pardridge","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.22450","article-title":"Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis","volume":"109","author":"Fortin","year":"2007","journal-title":"Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s11095-007-9379-0","article-title":"Blood-brain barrier transport of therapeutics via receptor-mediation","volume":"24","author":"Jones","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-3659(01)00321-2","article-title":"Tumor targeting by conjugation of DHA to paclitaxel","volume":"74","author":"Bradley","year":"2001","journal-title":"J. Control Release"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0163-7827(03)00033-X","article-title":"Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties","volume":"42","author":"Moghimi","year":"2003","journal-title":"Prog. Lipid Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"ref_128","unstructured":"Biden, J. (2024, February 24). FACT SHEET: The United States Announces New Investments and Resources to Advance President Biden\u2019s National Biotechnology and Biomanufacturing Initiative. White House, Available online: https:\/\/www.whitehouse.gov\/briefing-room\/statements-releases\/2022\/09\/14\/fact-sheet-the-united-states-announces-new-investments-and-resources-to-advance-president-bidens-national-biotechnology-and-biomanufacturing-initiative\/."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/6\/741\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:54:44Z","timestamp":1760108084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/6\/741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":128,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ph17060741"],"URL":"https:\/\/doi.org\/10.3390\/ph17060741","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}